Sino Biopharmaceutical (HKG:1177) presented the latest results of the phase III clinical study for benmelstobart injection in combination with anlotinib hydrochloride capsules at the American Society of Clinical Oncology's annual meeting
The drug is being tested as first-line treatment for non-small cell lung cancer in comparison with the pembrolizumab injection.
The study has achieved the primary study endpoint of progression-free survival, in which the median survival was prolonged by more than 6 months in the population with TPS ≥50%.
There was also a 40% reduction in the risk of disease progression and death as compared with the arm of pembrolizumab.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。